The structural economics of treatment vs prevention — why cures fund research better than prevention does

Healthcare systems and pharmaceutical markets exhibit a persistent structural imbalance: preventive interventions—vaccines, tobacco cessation, blood-pressure screening, early cancer detection, and lifestyle programs—are generally more cost-effective than treatment for established disease, yet funding and innovation incentives disproportionately flow toward treatment.